VIDEO: Vadadustat as safe, effective as darbepoetin alfa in CKD during dialysis
Click Here to Manage Email Alerts
In a video, Jay B. Wish, MD, clinical medicine professor at Indiana University School of Medicine reports the efficacy of vadadustat in treating anemia in patients with dialysis-dependent chronic kidney disease is noninferior to darbepoetin alfa.
Results from the global INNO2VATE phase 3 studies presented at ASN Kidney Week showed that vadadustat was noninferior to darbepoetin alfa for the time to first major adverse cardiovascular event (MACE), which was the primary safety endpoint.
“This shows, basically, that these are just as safe as [erythropoiesis stimulating agent (ESA)],” Wish, who is also co-chair of the Nephrology News & Issues Editorial Advisory Board, said in a video interview. “Everybody came away from that particular session feeling that the two treatments were pretty much noninferior or the same in terms of both safety and efficacy.”
Wish also explained that the dosing protocol is important to look at when determining efficacy because dose responsiveness is unclear before a patient begins treatment.
“You really can’t look at the initial efficacy, you have to look at the efficacy at 16 to 24 weeks or 24 to 36 weeks because that’s when you work out the dosing titration differences between the two groups,” he said.
Collapse
Eckardt K, et al. #TH-OR01. Presented at: ASN Kidney Week. Oct. 22-25 (virtual meeting).
Click Here to Manage Email Alerts